Tags

Type your tag names separated by a space and hit enter

Escitalopram in the treatment of obsessive-compulsive disorder.
Expert Rev Neurother. 2008 Mar; 8(3):339-49.ER

Abstract

Obsessive-compulsive disorder (OCD) is a chronic, distressing illness that is associated with a specific and unique response to selective serotonin reuptake inhibitors. Escitalopram was granted marketing authorization for the treatment of OCD from the European authorities in 2007 based on results from two Phase-III clinical trials in patients with moderate-to-severe OCD. One, a relapse prevention study, demonstrated substantial efficacy of escitalopram 10-20 mg/day in both acute and maintenance treatment, and the other demonstrated superior efficacy and favorable tolerability of escitalopram compared with placebo during 24-week, double-blind treatment. These data, and other studies reviewed here, suggest that escitalopram is an important additional tool for the treatment of OCD.

Authors+Show Affiliations

Chaim Sheba Medical Center, Department of Psychiatry, Tel Hashomer 52621, Israel. jzohar@post.tau.ac.il

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18345966

Citation

Zohar, Joseph. "Escitalopram in the Treatment of Obsessive-compulsive Disorder." Expert Review of Neurotherapeutics, vol. 8, no. 3, 2008, pp. 339-49.
Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert Rev Neurother. 2008;8(3):339-49.
Zohar, J. (2008). Escitalopram in the treatment of obsessive-compulsive disorder. Expert Review of Neurotherapeutics, 8(3), 339-49. https://doi.org/10.1586/14737175.8.3.339
Zohar J. Escitalopram in the Treatment of Obsessive-compulsive Disorder. Expert Rev Neurother. 2008;8(3):339-49. PubMed PMID: 18345966.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escitalopram in the treatment of obsessive-compulsive disorder. A1 - Zohar,Joseph, PY - 2008/3/19/pubmed PY - 2008/4/15/medline PY - 2008/3/19/entrez SP - 339 EP - 49 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 8 IS - 3 N2 - Obsessive-compulsive disorder (OCD) is a chronic, distressing illness that is associated with a specific and unique response to selective serotonin reuptake inhibitors. Escitalopram was granted marketing authorization for the treatment of OCD from the European authorities in 2007 based on results from two Phase-III clinical trials in patients with moderate-to-severe OCD. One, a relapse prevention study, demonstrated substantial efficacy of escitalopram 10-20 mg/day in both acute and maintenance treatment, and the other demonstrated superior efficacy and favorable tolerability of escitalopram compared with placebo during 24-week, double-blind treatment. These data, and other studies reviewed here, suggest that escitalopram is an important additional tool for the treatment of OCD. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/18345966/Escitalopram_in_the_treatment_of_obsessive_compulsive_disorder_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.8.3.339 DB - PRIME DP - Unbound Medicine ER -